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Abstract
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to deliver a scientiﬁc opinion on alginate-konjac-xanthan polysaccharide
complex (PGX) as a novel food (NF) submitted pursuant to Regulation (EC) No 258/97. The NF is an
off-white granular powder composed of three non-starch polysaccharides: konjac glucomannan,
xanthan gum and sodium alginate. The information provided on the composition, the speciﬁcations,
the batch-to-batch variability and the stability of the NF is sufﬁcient and does not raise safety
concerns. The production process is sufﬁciently described and does not raise concerns about the
safety of the NF. The applicant intends to add the NF to a variety of foods as well as to market the NF
in capsules. The recommended maximum daily intake of the NF from fortiﬁed foods and food
supplements is 15 g. The target population proposed by the applicant is adults from 18 to 64 years of
age. Considering the no observed adverse effect level of 1.8 g/kg body weight (bw) per day in a
subchronic toxicity study with PGX and the highest mean and 95th percentile anticipated daily intake
of NF from fortiﬁed foods, the margin of exposure (MoE) is 12 and 6, respectively, whereas the MoE
for the NF from food supplements is 9. The Panel concludes that the safety of the novel food, PGX, for
the intended uses and use levels as proposed by the applicant, has not been established.
© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to deliver a scientiﬁc opinion on alginate-konjac-xanthan polysaccharide
complex (PGX) as a novel food (NF) submitted pursuant to Regulation (EC) No 258/97 of the European
Parliament and of the Council. The assessment follows the methodology set out in Commission
Recommendation 97/618/EC. The assessment is based on the data supplied in the original application,
the initial assessment by the competent authority of Ireland, the concerns and objections of a scientiﬁc
nature raised by the other Member States and the responses of the applicant.
The NF is an off-white granular powder composed of three non-starch polysaccharides (NSP):
konjac glucomannan, xanthan gum and sodium alginate. These NSP are mixed in a speciﬁc ratio,
which has been claimed proprietary and conﬁdential by the applicant, and processed by a proprietary
process. The information provided on the composition, the speciﬁcations, the batch-to-batch variability
and the stability of the NF is sufﬁcient and does not raise safety concerns. The production process is
sufﬁciently described and does not raise concerns about the safety of the NF.
The applicant intends to add the NF to a variety of foods such as yoghurt, breads, biscuits, cereals,
pasta and juices. The applicant also intends to market the NF in capsules (750 mg NF per capsule).
The recommended maximum daily intake of the NF from fortiﬁed foods and food supplements is 15 g.
The target population proposed by the applicant is adults from 18 to 64 years of age.
By using individual data from the European Union (EU) dietary surveys and the maximum proposed
use levels for the NF, the mean and 95th percentile anticipated daily intake of the NF were estimated
(range of mean: 0.06–0.15 g/kg body weight (bw) which corresponds to 4.2–10.5 g/day based on an
adult bw of 70 kg; range of 95th percentile: 0.16–0.30 g/kg bw which corresponds to 11.2–21 g/day
based on an adult bw of 70 kg). The Panel notes that the estimate of the 95th percentile anticipated
daily intake of the NF from fortiﬁed foods would exceed the recommended maximum daily intake as
proposed by the applicant (15 g/day). However, the Panel notes that this intake estimate is based on
the conservative assumption that all proposed food items from all food categories consumed by an
individual actually contain the NF at the maximum proposed level of use. The recommended maximum
intake of the NF from food supplements is 13.5 g/day (which corresponds to 0.19 g/kg bw per day for
an adult bw of 70 kg).
Based on the nature of the NF, the Panel considers that the consumption of the NF is not
nutritionally disadvantageous.
Owing to its high water-holding capacity, when consumed with foods or beverages, the NF is able
to increase the volume and viscosity of gastric content, thereby affecting how material passes through
the digestive tract. A human study and an in-vitro study on PGX indicate that the NF is fermented by
the human intestinal microbiota.
Considering the nature of the NF, the Panel considers that the information provided does not raise
concerns with respect to genotoxicity of the NF.
A subchronic toxicity study in Sprague–Dawley rats, which received a diet containing 0% (control),
1.25%, 2.5% or 5% of PGX for 13 weeks showed statistically signiﬁcant increases in serum activities
of alanine transaminase (ALT) and aspartate transaminase (AST) in females in the high-dose group.
These effects, which indicate a toxic effect on the liver, were considered critical by the Panel.
Therefore the mid-dose, i.e. 2.5% PGX in the diet corresponding to 1.8 g/kg bw per day, was set as
the no observed adverse effect level (NOAEL) for this study.
Based on the results of repeated dose toxicity studies with the individual NSP of PGX as well as
with other types of ﬁbre, the Panel considers that it is not possible to conclude whether or not
increases in ALT and AST activity in rats (as observed in the provided 90-day repeated-dose toxicity
study with PGX) are related to the three individual NSP of PGX or other ﬁbre in general or to exclude
that the increases in ALT and AST activity in rats are speciﬁc to the NF.
Two double-blind, placebo-controlled intervention studies in adults, who were randomised to
consume PGX (at doses up to 10 and 15 g/day) or placebo for 3 or 14 weeks, respectively, reported
minor within-group increases in AST and ALT levels in the PGX group at week-3 and week-6 as
compared to baseline, respectively. Although the Panel considers that the magnitude of increases in
AST and ALT levels observed in these two human studies are not clinically relevant, the human data
are not sufﬁcient to draw conclusions on the effect of chronic consumption of PGX at the proposed
maximum use levels on liver enzymes.
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Considering the NOAEL of 1.8 g/kg bw per day and the highest mean and 95th percentile
anticipated daily intake of NF from fortiﬁed foods the margin of exposure (MoE) is 12 and 6,
respectively, whereas the MoE for the NF from food supplements is 9.
The Panel considers that the MoE for the NF at intended uses and use levels is not sufﬁcient for the
target population.
The Panel concludes that the safety of the novel food, PGX, for the intended uses and use levels as
proposed by the applicant, has not been established.
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1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
On 11 September 2014, the company InovoBiologic Inc. submitted a request under Article 4 of the
Novel Food Regulation (EC) No 258/971 to place on the market alginate-konjac-xanthan polysaccharide
complex (PGX) as a novel food (NF).
On 20 February 2015, the competent authority of Ireland forwarded to the Commission its initial
assessment report, which came to the conclusion that alginate-konjac-xanthan polysaccharide complex
(PGX) meets the criteria for acceptance of a NF deﬁned in Article (3)1 of Regulation (EC) No 258/97.
On 2 March 2015, the Commission forwarded the initial assessment report to the other Member
States (MS). Several MS submitted comments or raised objections.
The concerns of a scientiﬁc nature raised by the MS can be summarised as follows:
• In the speciﬁcations, the content for mercury was set above the maximum level permitted in
food supplements according to Regulation (EC) No 1881/2006.
• The speciﬁcations should include the identiﬁcation and quantiﬁcation of PGX complex and
impurities.
• Clariﬁcations were needed whether the NF was tested in laboratories which were accredited
under an internationally recognised system.
• A MS considered insufﬁcient that the stability data only reported viscosity. No information is
provided on whether the NF remains stable over 24 months in the food matrices to which the
NF is added.
• Some MS expressed their concerns that the consumption of the NF, especially as a food
supplement, on top of the consumption of ﬁbre from the diet, would result in exceeding the
EFSA recommended daily intake of ﬁbre (25 g/day).
• Concerns were expressed that some food categories to which the NF is proposed to be added,
are likely to be consumed by children (e.g. dairy desserts, puddings and biscuits).
• Concerns were raised on the lack of data on consumption of the NF in amounts greater than
15 g/day.
• The proposed use levels of the NF would lead to exceed the permissible use level of konjac as
food additive (1% in foods as indicated in Regulation 231/2012; acceptable daily intake of
3 g/day as recommended by the Scientiﬁc Food Committee).
• Concerns were expressed about absorption, distribution, metabolism and excretion of the NF
and the potential of the NF to affect absorption of nutrients such as minerals and vitamins.
• In the subchronic oral toxicity study by Matulka et al. (2009), statistically signiﬁcant differences
in some haematological, chemical and urine parameters were reported in the high-dose group
as compared with the control group. Some effects were dose-dependent and could not be
adequately explained. The high-dose tested in this subchronic toxicity study was applied to
humans without the use of an uncertainty factor.
• Potential undesirable effects (such as clumping) in the stomach and intestine should be
described.
• Considering the increase in the serum levels of vitamins D and C in the study by Carabin et al.
(2009), which lasted 21 days with a dose of 10 g/day of PGX, concerns were expressed on
long-term effects of the NF at the maximum proposed use levels.
• The choking risk posed by the NF is difﬁcult to assess, owing to the unknown relative
proportion of the three constituents of the NF. The management of choking risk when the NF
is added to foods has not been addressed.
In accordance with Article 29(1)(a) of Regulation (EC) No 178/20022, the European Food Safety
Authority (EFSA) is asked to carry out the additional assessment for PGX as a NF in the context of
Regulation (EC) No 258/97.
1 Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and
novel food ingredients. OJ L 43, 14.2.1997, p. 1–6.
2 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in
matters of food safety. OJ L 31, 1.2.2002, p. 1–24.
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EFSA is asked to carry out the additional assessment and to consider the elements of a scientiﬁc
nature in the comments raised by the other MS.
2. Data and methodologies
2.1. Data
The assessment of the safety of this NF is based on data supplied in the original application, the
initial assessment by the competent authority of Ireland, the concerns and objections of a scientiﬁc
nature of the other MS and the responses of the applicant.
In accordance with Commission Recommendation 97/618/EC3, PGX is allocated to Class 2.1, i.e.
‘complex Novel Food from non-genetically modiﬁed source, which has a history of food use in the
Community’. The data are required to comply with the information required for NF of Class 2.1, i.e.
structured schemes I, II, III, IX, X, XI, XII and XIII of Commission Recommendation 97/618/EC. In
the current scientiﬁc opinion, these structured schemes are listed in Sections 3.1–3.9. The intention is
to add the NF to foods and to market the NF as a food supplement. This assessment concerns only
risk that might be associated with consumption of the NF under the proposed conditions of use, and is
not an assessment of the efﬁcacy of the NF with regard to any claimed beneﬁt.
2.2. Methodologies
The assessment follows the methodology set out in Commission Recommendation 97/618/EC of
29 July 1997 concerning the scientiﬁc aspects and the presentation of information necessary to
support applications for the placing on the market of novel foods and novel food ingredients and the
preparation of initial assessment reports under Regulation (EC) No 258/97 of the European Parliament
and of the Council.
3. Assessment
3.1. Speciﬁcation of the Novel Food (NF)
The NF is an off-white granular powder which is composed of three non-starch polysaccharides (NSP):
konjac glucomannan, xanthan gum and sodium alginate. Upon EFSA’s request, the applicant conﬁrmed
that the three NSP are mixed in a speciﬁc ratio, which has been claimed proprietary and conﬁdential, and
processed by a proprietary process. The alginate-konjac-xanthan polysaccharide complex is named
PGX (IUPAC name: a-D-glucurono-a-D-manno-b-D-manno-b-D-gluco), (a-L-gulurono-b-D-mannurono),
b-D-gluco-b-D-mannan; CAS: 1189143-55-2). Other names for PGX are: PolyGlycopleX/alginate-konjac-
xanthan polysaccharide complex (USP/FCC); polysaccharide complex of konjac glucomannan (konjac),
sodium alginate and xanthan gum (polysaccharide complex KAX) (FDA); polysaccharide complex
(glucomannan, xanthan gum, sodium alginate) (Health Canada). The NSP in PGX are authorised as food
additives in the European Union (EU): konjac glucomannan as (E425 ii), xanthan gum as E 415 and
sodium alginate as E 401.
Several patents have been granted for PGX (e.g. in USA, Canada, Australia, Russia, China).
Proximate analysis of one batch of the NF is presented in Table 1.
3 Commission Recommendation 97/618/EC: Commission Recommendation of 29 July 1997 concerning the scientiﬁc aspects and
the presentation of information necessary to support applications for the placing on the market of novel foods and novel food
ingredients and the preparation of initial assessment reports under Regulation (EC) No 258/97 of the European Parliament and
of the Council. OJ L 253, 16.9.1997, p. 1–36.
Safety of alginate-konjac-xanthan polysaccharide complex (PGX)
www.efsa.europa.eu/efsajournal 7 EFSA Journal 2017;15(5):4776
The applicant claimed that PGX is a ‘novel complex’ rather than a mixture of the three NSP. In this
respect, different parameters have been compared between PGX and the three NSP: sedimentation,
precipitation, viscosity and macromolecular interactions (Abdelhameed et al., 2010; Harding et al.,
2011, 2012; Smith et al., 2014).
In the study by Abdelhameed et al. (2010), sedimentation velocity, which was tested with an
analytical ultracentrifugation technique, was increased for both PGX and the untreated mixture of the
NSP as compared to the single NSP. These observations indicate an interaction within the mixture of
the three NSP. This paper reports that there was a considerable amount of unreacted material,
particularly at low sedimentation coefﬁcients.
Harding et al. (2011) investigated the structure of each single NSP and the non-covalent
intermolecular interactions in the mixture of the three NSP unprocessed or processed with
EnviroSimplex® (TM1 and PGX, respectively) by using several analytical techniques (GC/MS, HPAEC/PAD
and 1H NMR). There were no changes, which might have occurred during the manufacturing process, in
the primary structure of the polysaccharides. The formation of a complex by intermolecular interactions
in aqueous solutions was indicated by the ﬂow behaviour of TM1 and PGX solutions, and supported by
the rheological behaviour of solutions of ternary mixtures containing variable alginate content, which
was enhanced by heat treatment. Sedimentation coefﬁcient distribution analysis from analytical
ultracentrifugation supports these observations, showing a clear shift to higher sedimentation
coefﬁcients in the heat-treated solutions of ternary mixtures as compared to the unheated material. In
another experiment, the addition of Ca2+ ions to either TM1 or PGX solutions did not induce precipitation
of calcium alginate, which implied that alginate is less accessible to Ca2+ ions owing to alternative
interactions with the other NSP. The authors concluded that the rheological measurements conﬁrmed
that non-covalent interactions occur in aqueous solutions of PGX.
Harding et al. (2012) reported that the intrinsic viscosity of PGX, which was measured with
analytical ultracentrifugation, was higher than the predicted value for the unprocessed mixture of the
three NSP. The authors concluded that there is a synergistic interaction among the three NSP in PGX,
which is sensitive to the ionic strength of the solvent.
Smith et al. (2014) investigated viscosity development over time for PGX and a blend of the three
NSP in aqueous solution. This study reported that the rate of dissolution and viscosity development
could be controlled by the EnviroSimplex® process, which is used to produce PGX.
According to the applicant, the studies above showed that PGX is a novel complex, in which the
primary structure of the NSP was unchanged and non-covalent intermolecular interactions among the
NSP occurred, which led to an increase in viscosity as compared to the single NSP.
The applicant also claimed that PGX develops a delayed viscosity as compared to the single NSP.
This delayed viscosity makes for a palatable product compared to konjac, which potentially can lead to
choking hazards due to rapid viscosity development.
The Panel raised safety concerns on the ability of PGX to form gels (in terms of capacity to absorb
water and rate at which viscosity develops) when PGX is consumed. In this respect, the applicant
clariﬁed that it takes approximately 25 min for PGX’s viscosity to start rising rapidly. The applicant
commented that in this time-period a person would consume a food in which PGX has been
incorporated and dispersed, and thus avoid problems of oesophageal obstructions.
The non-reversibility of PGX into the three single NSP has not been demonstrated.
Table 1: Proximate analysis of the NF
Parameter Method reference Result
Total calories Atwater factors 362 kcal/100 g
Carbohydrates Calculation 89.7 g/100 g
Total dietary ﬁbre AOAC 985.29 89.7 g/100 g
Total fat AOAC 996.06 < 0.10 g/100 g
Protein AOAC 992.23 0.80 g/100 g
Ash AOAC 950.14A 6.06 g/100 g
Moisture AOAC 925.09 4.14 g/100 g
AOAC: Association of Ofﬁcial Analytical Chemists.
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PGX speciﬁcations
In response to comments from MS and EFSA’s requests for clariﬁcations, the applicant revised the
speciﬁcations for PGX by including parameters on viscosity over time, pesticide residue and residual
solvents (ethanol). The applicant clariﬁed that PGX was tested for ethanol as ethanol was used when
processing konjac glucomannan. The maximum limit for mercury was reduced to 0.1 ppm. The
speciﬁcations for the NF with the relative methods of analysis are presented in Table 2. The applicant
indicated that the speciﬁcations of the NF are in line with the USP/FCC monograph for PGX. Test
results for three batches of PGX show compliance with the proposed speciﬁcations (Table 3). The
applicant provided the certiﬁcates of analysis of the starting materials (konjac glucomannan, xanthan
gum and sodium alginate), which showed compliance with the speciﬁcations for the respective food
additives as laid down in the Commission Regulation 231/2012. In particular, the certiﬁcate of analysis
for xanthan gum showed the absence of Xanthomonas campestris in the NF. The applicant indicated
that the laboratories where PGX was tested met the requirements in North America.
Table 2: Speciﬁcations of the NF
Parameter Method Speciﬁcation
Appearance Visual Powder
Colour Visual Off-white
Particle size USP<786> Monitor
Loss on drying 135°C oven – FCC 9th Ed. 3rd suppl. NMT 10%
Identiﬁcation
Test A (absence of konjac glucomannan) FCC 9th Ed. 3rd suppl. Conforms
Test B (absence of sodium alginate) FCC 9th Ed. 3rd suppl. Conforms
Test C (absence of xanthan gum) FCC 9th Ed. 3rd suppl. Conforms
Test D (viscometric characterisation) FCC 9th Ed. 3rd suppl. Conforms
Viscosity(a) over time
10 min 5 g in 350 mL H2O – FCC 9th Ed. 3rd suppl. 800–10,900 cP
60 min 5 g in 350 mL H2O – FCC 9th Ed. 3rd suppl. 16,400–42,200 cP
120 min 5 g in 350 mL H2O – FCC 9th Ed. 3rd suppl. 22,700–45,000 cP
Contaminants
Lead ICP NMT 0.6 ppm
Mercury ICP NMT 0.1 ppm
Cadmium ICP NMT 0.4 ppm
Arsenic ICP NMT 0.6 ppm
Pesticide residue USP<561> Meets USP limits
Residual solvents: ethanol USP<467> NMT 5,000 ppm
Microbiological parameters
Standard plate count USP<61> NMT 3,000 CFU/g
Yeast and mould USP<61> NMT 300 CFU/g
Escherichia coli USP<61>(b) Negative
Salmonella spp. USP<61>(b) Negative
Staphylococcus aureus USP<61>(b) Negative
Pseudomonas aeruginosa USP<61>(b) Negative
CFU: colony forming units; cP: centipoise; ICP: inductively coupled plasma; min: minutes; NMT: not more than; ppm: parts per
million; suppl.: supplement; USP/FCC: United States Pharmacopeia/Food Chemicals Code.
(a): Viscosity is measured on a Brookﬁeld type rotational viscometer at room temperature.
(b): The average microbial counts obtained for the total aerobic count and the total yeast and mould count, must be ≥ 50% and
≤ 200% of those obtained from the positive control inoculum plates.
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The Panel considers that the information provided on the composition, the speciﬁcations and the
batch-to-batch variability of the NF is sufﬁcient and does not raise safety concerns.
3.1.1. Stability of the NF
PGX is claimed by the applicant to be stable for 2 years from the date of manufacture when stored
in tight containers under a cool, dry environment at room temperature between 15°C and 30°C, away
from direct sunlight.
The applicant provided the results on viscosity for two batches of PGX up to 24 and 54 months,
respectively. Upon EFSA’s request for clariﬁcations on the high and variable viscosity over time for
these two batches, the applicant commented that the variability of viscosity was probably due to the
analysis being performed by different operators with different instruments.
Based on the data provided and the low water content, the Panel considers that the NF is
sufﬁciently stable.
3.1.2. Stability under the intended conditions of use
No information has been provided by the applicant on the stability on the NF when added to foods.
Table 3: Analysis of three batches of the NF
Batch analysis results
Parameter Speciﬁcation
Lot number
902310
Lot number
902870
Lot number
903023
Appearance Powder Conforms Conforms Conforms
Colour Off-white Conforms Conforms Conforms
Particle size Monitor Not reported Not reported Not reported
Loss on drying NMT 10% 5 5 4
Identiﬁcation
Test A (absence of konjac
glucomannan)
Conforms Conforms Conforms Conforms
Test B (absence of sodium
alginate)
Conforms Conforms Conforms Conforms
Test C (absence of xanthan gum) Conforms Conforms Conforms Conforms
Test D (viscometric
characterisation)
Conforms Conforms Conforms Conforms
Viscosity over time
10 min 800–10,900 cP 3,500 8,000 8,400
60 min 16,400–42,200 cP 20,700 41,900 41,400
120 min 22,700–45,000 cP 27,500 42,300 43,200
Contaminants
Lead NMT 0.6 ppm 0.5 0.5 0.4
Mercury NMT 0.1 ppm < 0.1 < 0.1 < 0.1
Cadmium NMT 0.4 ppm 0.1 0.08 0.07
Arsenic NMT 0.6 ppm 0.3 0.3 0.5
Pesticide residue Meets USP limits Conforms Conforms Conforms
Residual solvent: ethanol NMT 5,000 ppm Not detected 236 311
Microbiological parameters
Standard plate count NMT 3000 CFU/g 1,100 300 100
Yeast and mould NMT 300 CFU/g < 20; 20 < 20; < 20 < 20; < 20
Escherichia coli Negative Negative Negative Negative
Salmonella spp. Negative Negative Negative Negative
Staphylococcus aureus Negative Negative Negative Negative
Pseudomonas aeruginosa Negative Negative Negative Negative
CFU: colony forming units; cP: centipoise; ppm: parts per million; NMT: not more than.
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Upon EFSA’s request for clariﬁcation on viscosity when PGX is added to foods, the applicant
commented that it is not feasible to test PGX in the variety of food matrices to which it is expected to
be added.
The Panel considers that no conclusions can be drawn on the stability of the NF when added to foods.
3.2. Effect of the production process applied to the NF
PGX is produced in accordance with Good Manufacturing Practice. Konjac glucomannan, xanthan
gum and sodium alginate are tested for compliance to speciﬁcations. The NSP are mixed in a speciﬁc
proprietary ratio, which has been claimed conﬁdential by the applicant. The mixture is placed in the
EnviroSimplex® agglomerator (a ﬂuidised bed reactor) with 30–60% wt/wt water at no more than
110°C, for about 20 min. No processing aids are used. The material then passes through several
chambers until the product reaches room temperature after a further 40 min retention time in the
EnviroSimplex® agglomerator. The resulting complexed polysaccharide is evaluated by Quality Control,
packaged and then placed into storage. The ﬁnal product is available as an off-white granular powder.
Upon EFSA’s request for clariﬁcations, the applicant indicated that PGX is packaged in two different
particle sizes, one being used for meal replacement in Canada and USA (PGX100), and the other one
(PGX300) that is intended to be marketed in EU and has been used in clinical trials.
The Panel considers that the production process is sufﬁciently described and does not raise safety
concerns.
3.3. History of the organism used as a source of the NF
The three NSP which constitute PGX (konjac glucomannan, xanthan gum, sodium alginate) have
been authorised as food additives in the EU.
Konjac glucomannan, which is obtained from the tuber of the perennial plant
Amorphophallus konjac, is a water-soluble high-molecular-weight polysaccharide, consisting of
D-mannose and D-glucose units which are connected by b(1-4)-glycosidic bonds. Konjac ﬂour, the
unpuriﬁed raw product from which glucomannan is isolated, has been used for centuries in traditional
Eastern Asian cooking. Both konjac ﬂour and konjac glucomannan are used as food additives. For this
purpose, konjac ﬂour (INS No 425) has been evaluated by the Joint FAO/WHO Committee on Food
Additives (JECFA) (JECFA, 1993a, 1997). In the EU, the Scientiﬁc Committee for Food (SCF) has evaluated
konjac glucomannan (E 425 ii) and konjac gum (E 425 i), which is another product derived from konjac
ﬂour (SCF, 1997). The Committee could not derive an acceptable daily intake (ADI) for either konjac
glucomannan or konjac gum but considered their use, e.g. as a thickener, emulsiﬁer, stabiliser and
gelling agent, up to 1% in food acceptable, provided that the total intake from all sources does not
exceed 3 g/day. Konjac glucomannan or konjac gum should not be used to produce dehydrated
foodstuffs intended to rehydrate on ingestion. Consumption of glucomannan may cause serious choking
if used with insufﬁcient ﬂuid (Health Canada, 2010). Konjac glucomannan, which is used as a starting
material to produce PGX, meets the speciﬁcations for the food additive E425 ii as laid down in the
Commission Regulation (EU) No 231/2012.
Xanthan gum is a high-molecular-weight polysaccharide produced by the bacterium
Xanthomonas campestris, which has been recommended by EFSA to be included in the qualiﬁed
presumption of safety list of biological agents (EFSA BIOHAZ Panel, 2015). Xanthan gum is an acidic
polymer constituted by a cellulose backbone, which has trisaccharide side-chains of mannose-glucuronic
acid-mannose linked to every second glucose unit in the main chain. Xanthan gum (INS No 415) was
evaluated by JECFA, and the Committee accepted the use as food additive without derivation of a
numerical ADI (ADI ‘not speciﬁed’) (JECFA, 1987). The ADI ‘not speciﬁed’ was later endorsed by the SCF
(1992). Xanthan gum is used for example as an emulsiﬁer, stabiliser and thickener in foods. Xanthan
gum, which is used as starting material to produce PGX, meets the speciﬁcations for the food additive
E 415 as laid down in the Commission Regulation (EU) No 231/2012.
Sodium alginate is a salt of alginic acid, a polysaccharide extracted from brown seaweed
(particularly kelp). The chemical structure consists of blocks of (1,4) linked-b-D-polymannuronic acid,
(1,4) linked-a-L-polyguluronic acid and alternating blocks of the two uronic acids. Sodium alginate (INS
No 401) has been evaluated by JECFA together with alginic acid and its ammonium, calcium and
potassium salts, and the Committee allocated a group ADI ‘not speciﬁed’ (JECFA, 1993b). In the EU,
alginic acid and alginates were evaluated by the SCF, which endorsed the JECFA assessment for alginic
acid and its sodium, potassium and calcium salts (SCF, 1994). Sodium alginate is used as a gelling
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agent, stabiliser and thickener in foods. Sodium alginate, which is used as a starting material to
produce PGX, meets the speciﬁcations for the food additive E 401 as laid down in the Commission
Regulation (EU) No 231/2012.
3.4. Anticipated intake/extent of use of the NF
The applicant intends to add the NF to a variety of foods: Table 4 presents the uses and maximum
use levels of the NF. The applicant also intends to market the NF as a food supplement (capsules;
750 mg NF per capsule).
The recommended maximum intake of the NF from all sources (i.e. from fortiﬁed foods and food
supplements) is 15 g/day. The Panel notes that the consumption of glucomannan in the NF exceeds
3 g/day (SCF, 1997).
The target population proposed by the applicant is adults from 18 to 64 years of age.
Consumers will be instructed to drink 375–500 mL of ﬂuids immediately after the consumption of
the NF, whether added to foods/beverages or taken as a food supplement, in order to reduce the risk
of bowel obstruction.
The applicant indicates that ﬁnal products will be labelled to be consumed by low-ﬁbre consumers
and not to be consumed by children.
3.4.1. Anticipated intake from fortiﬁed foods
Based on the data from the UK National Diet and Nutrition Survey (NDNS) for 2000–2001 (Hoare
et al., 2004) and the proposed maximum use levels, the applicant estimated the daily intake of the NF
for adults. The applicant calculated the 97.5th percentile daily intake of the NF by doubling the mean
of the daily intake of the NF. The Panel considers that this is not an appropriate method to estimate a
high-level of intake.
A detailed assessment to estimate the daily intake of the NF at the maximum proposed use levels,
using individual data from EU dietary surveys was performed (EFSA, 2011). Among the EU dietary
surveys, the mean anticipated daily intake of the NF for adults ranges from 0.06 to 0.15 g/kg bw
(4.2–10.5 g/day based on an adult bw of 70 kg), whereas the 95th percentile anticipated daily intake
ranges from 0.16 to 0.30 g/kg bw (11.2–21 g/day based on an adult bw of 70 kg).
The Panel notes that the estimate of the 95th percentile anticipated daily intake of the NF from
fortiﬁed foods would exceed the recommended maximum daily intake as proposed by the applicant
(15 g/day). However, the Panel notes that this intake estimate is based on the conservative
assumption that all proposed food items from all food categories indicated in Table 4 consumed by an
individual actually contain the NF at the maximum proposed level of use.
Table 4: Proposed uses and maximum use levels of the NF
Food category
Maximum use level of the NF
(g per 100 g)
Yoghurt 1.1
Dairy desserts and puddings (e.g. ice cream, ice cream bars,
frozen yoghurt)
0.67
Breads (white and whole wheat) 5
Milkshakes 1.04
Biscuits/cookies 8.3
Cereals (e.g. ﬂaked cereal) 8.3
Cereal bars (breakfast bars, granola type bar) 6.25
Noodles 1.79
Pasta 3.9
Cereal beverage 1.04
Fruit juices and fruit smoothie-type drinks 1.04
Vegetable juices 1.04
Canned fruit 1.79
Single serve combination meals (e.g. Teriyaki chicken, lasagne) 1.0
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3.4.2. Anticipated intake from food supplements
The applicant indicated that the maximum intake of the NF from food supplements is 13.5 g/day
(6 capsules of 750 mg of the NF per meal, for a total of 18 capsules per day), which corresponds to
0.19 g/kg bw per day for an adult bw of 70 kg (EFSA Scientiﬁc Committee (2012).
3.4.3. Combined intake from fortiﬁed foods and foods supplements
Based on the 95th percentile of the anticipated daily intake of the NF from fortiﬁed foods, the
combined intake of the NF from fortiﬁed foods and food supplements would range from 24.7 to
34.5 g/day. The Panel notes that the combined anticipated daily intake of the NF would exceed the
recommended maximum daily intake as proposed by the applicant (15 g/day).
3.4.4. Intake of ﬁbre from the background diet
The Panel notes that consumers of the NF would also be exposed to ﬁbre from their background
diet. In adults, average ﬁbre intakes from the diet range from 15 to 30 g/day; ranges of ﬁbre intake
vary from 6 to 9 g/day (5th percentile) to 39–51 g/day (95th percentile) (EFSA, 2010)).
3.5. Information from previous exposure to the NF or its source
PGX has been sold in Canada and USA since 2004 (as food supplements or added to foods). A total
of 58 million single servings of PGX-containing products have been sold. Approximately 1,800 adverse
events have been reported (Carabin et al., 2010). The majority of the reported adverse events (around
43%) were related to gastrointestinal symptoms (e.g. heartburn, nausea, abdominal pain/cramps).
3.6. Nutritional information on the NF
Although the NF is a mixture of NSP and as such may be considered as ﬁbre, the applicant
suggests an energy conversion factor of 15 kJ/g (3.6 kcal/g) (see Table 1). This assumes that all the
ingested NF will be fermented by the colonic microbiota and that resulting degradation products will be
absorbed and fully energetically available. The Panel notes that the energy conversion factor used for
ﬁbre is 2 kcal/g.4
In response to a comment from a MS on the potential effect of the NF on the bioavailability of
nutrients, the applicant indicated that consuming PGX is not different from consuming other ﬁbre and
referred to the study by Rattan et al. (1981).
The Panel notes that there is little evidence that a high intake of dietary ﬁbre as part of an overall
healthy diet will produce signiﬁcant deleterious effects in healthy people (Wisker et al., 1991;
Greenwood et al., 2003; IOM, 2005) and that a tolerable upper intake level is not set for dietary ﬁbre.
The applicant provided publications on animal and human studies on effects of soluble ﬁbre (e.g.
cellulose, guar gum, oligofructose, konjac glucomannan meals) on mineral absorption. The
Panel considers that no conclusions can be drawn from these studies on an effect of the NF on the
bioavailability of minerals.
With regard to concerns raised by MS that the NF might impact bioavailability of minerals and
vitamins, the applicant referred to a double-blind, placebo controlled intervention study by Carabin
et al. (2009), in which 54 healthy subjects (aged 18–55 years) were randomised to consume either
PGX (n = 27, 14 males) or placebo (skimmed milk powder; n = 27, 11 males) with cereals and yoghurt
for 3 weeks. After an initial dose of 5 g/day of PGX in the ﬁrst week, participants consumed 10 g/day
of PGX in the second and third week. This study reported plasma levels of sodium, potassium,
chloride, calcium, magnesium, zinc, vitamin A, B1, B6, B12, E, K, C and 1,25-dihydroxyvitamin D.
Despite the limited value of some of these biomarkers for assessing nutritional status, the
Panel considers that the study provided does not raise concerns.
Based on the nature of the NF, the Panel considers that the consumption of the NF is not
nutritionally disadvantageous.
4 Regulation (EC) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food
information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and of
the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/EC,
Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC and
Commission Regulation (EC) No 608/2004. OJ L 304/18, 22.11.2011, p. 1–46.
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3.7. Microbiological information on the NF
To ensure the absence of contaminating microorganisms, PGX is tested for Escherichia coli,
Salmonella, Staphylococcus aureus, Pseudomonas aeruginosa, yeast and mould as described in the
speciﬁcations (Table 2).
Xanthan gum, one of the NSP used in PGX, is produced by a pure-culture fermentation of
carbohydrates with the bacterium Xanthomonas campestris. Upon a request for clariﬁcation from
EFSA, the applicant provided a certiﬁcate of analysis for xanthan gum that indicated the absence of
Xanthomonas campestris in the NF.
The Panel considers that the microbiological information provided does not raise safety concerns.
3.8. Toxicological information on the NF
3.8.1. Absorption, distribution, metabolism and excretion
The NF is a complex of water-soluble NSP with a very high water-holding capacity. When consumed
with foods or beverages, the NF is able to increase the volume and viscosity of gastric content,
thereby affecting how material passes through the digestive tract.
In a randomised, double-blind, placebo-controlled study, Reimer et al. (2012a) examined faecal
short-chain fatty acids (SCFA) concentrations in healthy subjects on a low-ﬁbre background diet
(approximately 10 g/day) who were allocated to consume either 5 g/day of PGX in a ﬁrst week and
10 g/day during the following 2 weeks (PGX group, n = 27), or a placebo consisting of skimmed milk
powder (control group, n = 27). Acetate decreased over time in the control but not in the PGX group,
which resulted in higher concentrations of acetate in the PGX group at the ﬁnal visit as compared to
the control group (p = 0.018). There were no differences in propionate, butyrate, valerate, caproate or
lactate concentrations between the groups. Repeated-measures analysis of variance showed a
signiﬁcant treatment effect (p = 0.03) for total SCFA, which was higher in the PGX group vs control
subjects.
In another study, Reimer et al. (2014) investigated the fermentability (through NaOH consumption)
and production of SCFA (acetate, propionate, butyrate) and branched chain fatty acids (BCFA) of PGX
as compared to fructo-oligosaccharide (FOS) and cellulose in an in vitro model which simulates the
human large intestine. This study reported that NaOH consumption for PGX was higher as compared
to cellulose, whereas it was lower as compared to FOS. Acetate and butyrate production were higher
for PGX as compared to cellulose, whereas they were not different as compared to FOS. Propionate
production was higher for PGX as compared to cellulose and FOS. Total BCFA production with PGX was
lower than cellulose, but higher than FOS. The authors concluded that PGX is fermented by the colonic
microbiota.
The Panel notes that one study in human subjects and one in-vitro model on the human large
intestine indicate fermentability of the NF by human intestinal microbiota.
3.8.2. Genotoxicity
The applicant provided a publication on two studies on the potential mutagenicity of PGX (Marone
et al., 2009). According to the authors, these studies were conducted in compliance with the
Organisation for Economic Co-operation and Development (OECD) principles of good laboratory
practice (GLP) (OECD, 1998b) and according to the OECD test guideline for the bacterial reverse
mutation test (test guideline No 471; OECD, 1997a) and the mammalian erythrocyte micronucleus test
(test guideline No 474; OECD, 1997b), respectively.
In the bacterial reverse mutation assay (Ames test) using Salmonella Typhimurium strains TA 98,
TA 100, TA 1535, and TA 1537 and the Escherichia coli strain WP2 uvrA, PGX was tested in the
presence or absence of a metabolic activation system (S9-mix), using the plate-incorporation and
pre-incubation methods. Due to solubility problems, only doses up to 100 lg/plate could be tested. At
the tested dose levels, PGX did not cause relevant increases in revertant colony numbers in any of the
ﬁve strains with or without metabolic activation system. This study thus showed no mutagenicity of
PGX up to the highest tested dose level of 100 lg/plate.
For the mammalian erythrocyte micronucleus test, a cottonseed oil extract of PGX was prepared
and administered intraperitoneally to NMRI mice (ﬁve/sex per group) at dose levels designated 100%,
50% and 20% extract. Owing to the bulk properties of PGX, a cottonseed oil extract of PGX was used
in this study. The highest tested dose (100% extract) produced signs of toxicity in a preliminary
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experiment. In the main experiment, toxicity symptoms (e.g. reduction of spontaneous activity, rough
fur, prone position, palpebral closure, and constricted abdomen) were observed at the highest dose
level; weak or moderate toxicity symptoms were observed at the lower dose levels. Peripheral blood
was taken 44 hours after the administration from animals of each treatment group, the negative and
the positive control groups, and 68 hours after the administration from animals of the negative control
group and a second high-dose group. Blood cell populations were discriminated using speciﬁc
antibodies and analysed by ﬂow cytometry. The percentage of polychromatic (immature) erythrocytes
(PCE) relative to total erythrocytes (= relative PCE) as well as the ratio of micronucleated PCE to total
PCE were determined. Treatment with the PGX extract did not cause an increase in the incidence of
micronucleated PCE compared with the negative control group. All mean values were within the range
of the historical control data of the laboratory. The positive control cyclophosphamide induced the
expected statistically signiﬁcant increase. According to the author, the relative PCE was statistically
signiﬁcantly reduced in males at the 44 h time point, indicating that the target tissue was exposed.
However, the Panel notes some inconsistencies regarding the information on statistical signiﬁcance in
the publication. Despite this and another limitation in data reporting (no individual animal data were
shown), the Panel concludes that the study provided no indications of clastogenicity and/or
aneugenicity of the tested PGX extract.
Considering the nature of the NF, the Panel considers that the information provided does not raise
concerns with respect to genotoxicity of the NF.
3.8.3. Repeated dose toxicity studies
A repeated dose subchronic toxicity study with PGX was provided by the applicant. In addition,
publications on animal studies with PGX using speciﬁc disease models, publications on studies with the
three individual NSP of PGX or with other ﬁbre have been considered in this section.
Subchronic toxicity study with PGX
The applicant provided a subchronic toxicity study, which was conducted in compliance with the
OECD principles of GLP and in accordance with OECD Test Guideline No. 408 (OECD, 1998a,b).
Sprague–Dawley rats (ten/sex per group, housed singly; 7–8 weeks of age) were fed a standard
rodent diet containing 0% (control group), 1.25%, 2.5% or 5% PGX for 92 days (Euroﬁns, Product
Safety Laboratories, 2008; Matulka et al., 2009). The test and control diets, as well as water, were
provided throughout the study to ensure ad libitum feeding. The mean overall daily intake of PGX in
males and females, respectively, was calculated to be approximately 0.8 and 0.9 g/kg bw in the 1.25%
group, 1.6 and 1.8 g/kg bw in the 2.5% group, 3.2 and 3.8 g/kg bw in the 5% group.
Upon EFSA request for clariﬁcation, the applicant indicated that the test material used in the 90-day
study had been produced in the same way as the NF using the same proprietary ratio of the three
NSP. The Panel considers that the test material is representative of the NF.
There were no mortalities during the treatment period. Detailed clinical observations of the animals
conducted weekly revealed transient clinical signs including light brown faeces for one female in the
2.5% group (day 57), all 5% group males (days 57 and 64) and two (day 57) and six (day 64) females
in the 5% group. One male and one female in the 5% PGX group were found emaciated on day 57 and
day 92, respectively; these ﬁndings were not considered test substance-related, by the authors of the
study. In the case of the male animal, it was attributed to a faulty valve in the water supply. No such
reason could be identiﬁed for the female animal. Additional ﬁndings in this animal were reduced body
weight, body weight gain, food consumption, food efﬁciency, reduced absolute and relative thymus
weights, as well as slight atrophy of the thymus in histopathological examinations. Therefore, in view of
the Panel, it cannot be excluded that this effect is due to application of the test substance.
In ophthalmoscopic examinations before the start and at the end of the treatment period, the animals’
eyes were considered normal. Results from ‘Functional Observational Battery’ (FOB) and motor activity
tests in rats fed PGX showed no relevant differences when compared to those of the control group.
Mean body weights, body weight gains, feed consumption and feed efﬁciency in the groups
administered PGX were comparable to those in the control group.
Relevant ﬁndings observed in the study by Matulka et al. (2009) are presented in Table 5. Male rats
fed a diet with 5% PGX showed a statistically signiﬁcant decrease in red blood cell count (3.7%;
p < 0.05) compared with the control group. In the absence of signiﬁcant changes in other
haematology and coagulation parameters in males and females, this slight change is not considered
toxicologically relevant. Clinical chemistry analysis showed a statistically signiﬁcant increase in the
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serum albumin concentration in male rats of the high-dose group (6.5%; p < 0.05). Since there were
no signiﬁcant differences in other clinical chemistry parameters in male animals, this slight change is
not considered toxicologically relevant. For high-dose females, statistically signiﬁcant increases were
noted in serum aspartate aminotransferase (AST) activity (20%), alanine aminotransferase (ALT)
activity (69%) and triglyceride (TG) concentration (36%). The increase in TG concentration (and a
non-signiﬁcant increase in cholesterol concentration) may be regarded as an effect on liver function
and general metabolism, which does not necessarily constitute an adverse effect. However, the
magnitude of the effect on transaminases and the pattern of these changes (ALT > AST), which is
typical for liver toxicity raise concerns regarding liver toxicity. Signiﬁcant decreases in serum electrolyte
levels, i.e. sodium (5%), potassium (6%) and chloride levels (4%) (p < 0.05), also occurred. These
changes may be attributable to increased ﬂuid loss, which is accompanied by other urinalysis ﬁndings,
i.e. increased urine volume (> +110% in both sexes), and reduced gravity and protein content in high-
dose females (and males). The authors of the publication argued that the diet was provided in powder
form, and the high oral viscosity of PGX may have increased water intake. However, water intake of
the animals was not measured in this study. A statistically signiﬁcant decrease in the inorganic
phosphorous concentration (16.9%) was found only in mid-dose females and is thus considered an
incidental ﬁnding. Upon EFSA’s request for additional information, the applicant provided historical
control data for those parameters, which showed statistically signiﬁcant differences. The Panel notes
the broad range of values for the historical control data, which were collected over a period of 10
years, and considers that the data are not suitable to overrule the concerns raised from this study.
At necropsy, no gross abnormalities attributable to the test material were identiﬁed. Incidental
ﬁndings included ﬂuid-ﬁlled uteri in some females in all groups, and a light brown encapsulated ﬁrm
mass, anteriomedial of the right testis in one male of the mid-dose group, for which there were no
corresponding histological ﬁndings. Organ weight determinations showed no statistically signiﬁcant
differences in absolute or relative organ weights (relative to body and brain weight) between PGX-
treated groups and the control group. Microscopic analysis of selected organs and tissues (including
liver and kidneys) found that the histopathological changes were of a type commonly observed in
control laboratory rats, and occurred with comparable incidence in the control and high dose groups.
The Panel considers the increased serum activities of ALT and AST in females in the high-dose
group (i.e. 5% PGX in the diet), which indicate a toxic effect on the liver, as critical effects. Therefore,
the mid-dose, i.e. 2.5% PGX in the diet corresponding to 1.8 g/kg bw per day, is regarded as the no
observed adverse effect level (NOAEL).
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Studies with disease models
The applicant has also referred to studies which investigated the effect of 5% PGX in disease
models for type II diabetes. In the studies by Grover et al., (2011a,b) and Reimer et al. (2012b),
Zucker diabetic rats were used, whereas in the study by Reimer et al. (2011) Sprague–Dawley rats,
which consumed a diet with 65% sucrose, were used. Study durations ranged from 6 up to 43 weeks,
the latter occurring in the study with the high sucrose-diet. Control groups received the same amount
of cellulose or inulin, to identify speciﬁc effects of PGX in comparison to other ﬁbre. Food intake was
decreased in all studies, compared to the other ﬁbre, in some studies accompanied also by lower body
weight or body weight gain. No adverse effects were reported with respect to cholesterol, TG, ALT,
AST, alkaline phosphatase, bilirubin, histopathology of the kidney or liver.
Repeated dose toxicity studies with three individual NSP of PGX or other ﬁbre
In order to evaluate whether the effect on liver enzymes in rats in the subchronic toxicity study by
Matulka et al. (2009) is compound related or incidental, the Panel analysed data on the three
constituents based on the reviews by JECFA and the SCF (JECFA, 1987, 1993a,b, 1997, SCF, 1992,
1994, 1997). No increases in ALT plus AST activities in rodent toxicity studies were observed. The
Panel notes that the more recent publication by Hagiwara et al. (2004) on a 90-day study with
xanthan gum reported an increase in ALT activity in a 90-day female F344 rats. However, the increase
was not dose-related and statistically signiﬁcant only at the mid-dose level.
Furthermore, to determine whether liver ﬁndings may be a general effect of ﬁbre, the applicant
was requested to retrieve studies on the effect of ﬁbre on liver in rats. In its reply, the applicant
indicated that among around 400 articles which were retrieved on the effects of ﬁbre in rats, only
three studies reported similar effects as those observed in the study by Matulka et al. (2009), i.e. the
study by Kotkoskie and Freeman (1998) on ethylcellulose, by Lina and B€ar (2004) on b-cyclodextrin,
and by Doi et al. (2006) on gum Arabic.
The Panel considers that it is not possible to conclude whether or not increases in ALT and AST
activity in rats (as observed in the provided 90-day repeated-dose toxicity study with PGX) are related
to the three individual NSP of PGX or other ﬁbre in general or to exclude that the increases in ALT and
AST activity in rats are speciﬁc to the NF.
3.8.4. Human studies
The applicant provided 13 articles on human studies with the NF.
Six of these studies investigated the effect of single doses of PGX, up to 7.5 g, consumed as
capsules or granules dissolved in water or added to foods, on glycaemic index of starchy foods or on
post-prandial glucose levels, satiety, food intake or palatability in healthy adults or adolescents (Vuksan
et al., 2009; Brand-Miller et al., 2010, 2012; Jenkins et al., 2010a,b; Solah et al., 2014). These studies
did not observe or report adverse effects. The Panel considers that no conclusions on the safety of the
NF can be drawn from these studies due to low and single doses investigated.
In the double-blind, cross-over study by Kacinik et al. (2011) on appetite ratings, 45 overweight
and obese women were randomised to consume PGX (15 g/day) or placebo in a low calorie diet for
three days. The Panel considers that no conclusions on the safety of the NF can be drawn from this
study owing to the short duration of consumption of the NF.
Obese and overweight adults consumed PGX, up to 15 g/day, together with meal replacements for
12 weeks in the single-arm (no control group) studies by Reichert et al. (2013a,b). Changes from
baseline in anthropometric parameters were investigated. These studies did not record adverse effects.
The Panel considers that no conclusions on the safety of the NF can be drawn from these uncontrolled
studies.
In the double-blind, controlled intervention study by Lyon et al. (2011), 59 obese or overweight
adults were randomised to consume either PGX (n = 29) or inulin (n = 30) with yoghurt for 15 weeks.
The daily dose of 6 g of PGX in the ﬁrst week was increased to 10 g/day during the second week and
then to 15 g/day from the third week up to week-15. There was no between-group difference with
regard to TG, whereas a decrease in total, high-density lipoprotein (HDL) and low-density lipoprotein
(LDL) cholesterol was observed only in females in the PGX group as compared to females in the inulin
group. No between-group difference was reported in the number of participants with at least one
adverse effect of gastrointestinal origin. No serious adverse events were reported. The Panel notes
that this study was not designed for assessing safety and did not include a placebo group, however,
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the Panel considers that this study provides no indications that consumption of 15 g PGX for 3 months
would raise safety concerns.
Twenty-nine overweight or obese adults (6 men) were included in a clinical weight-loss programme
at the Canadian Centre for Functional Medicine (Lyon and Reichert, 2010). Participants consumed
10–15 g of PGX per day for 14 weeks. A total of 32% of participants experienced mild gastrointestinal
side effects (e.g. gas, bloating, constipation, loose stools) which did not lead to discontinuation of the
study. Sixty-eight per cent of these gastrointestinal symptoms resolved within approximately the ﬁrst
3 weeks of the study. The Panel considers that no indications for safety concerns can be inferred from
this study.
In the double-blind, placebo-controlled intervention study by Carabin et al. (2009), 54 healthy
subjects (aged 18–55 years) were randomised to consume either PGX (n = 27, 14 males) or placebo
(skimmed milk powder; n = 27, 11 males) with cereals and yoghurt, for 3 weeks. The initial dose of
5 g/day of PGX in the ﬁrst week was followed by a dose of 10 g/day in the second and third week.
ANOVA or Mann–Whitney–Wilcoxon test were used to compare data between groups.
No statistically signiﬁcant between-group differences were reported in AST and ALT serum levels.
Upon request by EFSA, the applicant provided AST and ALT serum levels at baseline, at week-1 and
week-3 for each group and conducted a post-hoc power analysis for AST and ALT levels. A within-
group analysis showed that in the PGX group, there was a small, statistically signiﬁcant increase of
10% in AST (20.3  4.4 IU/L vs 22.4  5.2 IU/L, change 2.1  4.2 IU/L, p = 0.039) and a non-
signiﬁcant increase of 14% in ALT serum levels (16.4  6.4 IU/L vs 18.7  10.0 IU/L, change
2.3  7.3 IU/L, p = 0.063) at week-3 as compared to baseline. The Panel notes that the changes in
AST and ALT levels were within normal range values.
No between-group difference was reported in the other parameters investigated (stool, urinary,
haematological, biochemical parameters; gastrointestinal discomfort symptoms), except for total and
LDL cholesterol, gamma-glutamyl transpeptidase and uric acid levels which had a greater decrease in
the PGX group as compared to the placebo group. No serious adverse events were reported.
The Panel considers that this study in 54 volunteers provides no indication that the consumption of
PGX up to 10 g/day for 3 weeks would raise safety concerns. No conclusions can be drawn from this
study with regard to possible adverse effects associated with long-term consumption of PGX at the
maximum use level proposed by the applicant (i.e. 15 g/day).
In the double-blind, placebo-controlled intervention study by Reimer et al. (2013), 64 overweight
Japanese adults (28 men) were randomised to consume either PGX (n = 32) or placebo (rice ﬂour;
n = 32) with yoghurt for 14 weeks. The initial PGX daily dose of 5 g was increased to 10 g at day 4,
and then to 15 g from day 8 until week-14.
Fifty-six participants completed the study and were included in the analysis (n = 28 in each group).
One participant in the PGX group withdrew from the study owing to diarrhoea. Repeated measures
ANOVA was used to compare data between groups.
No statistically signiﬁcant between-group differences were reported in AST and ALT levels. Upon
request by EFSA, the applicant provided AST and ALT levels at baseline, at week-6 and week-14 for
each group and conducted a post-hoc power analysis for AST and ALT parameters. A within-group
analysis showed that at week-6, ALT was 30.5  16.2 IU/L, which is still within the reference range,
but was signiﬁcantly higher than the baseline value of 23.9  13.0 IU/L, for a change of
6.7  10.0 IU/L in the PGX group (p = 0.003), whereas the increase in the placebo group was non-
signiﬁcant (2.2  8.9 IU/L). This within-group analysis also showed that in the PGX group at week-14,
the increases of 7% in AST levels and 20% in ALT levels were non-signiﬁcant as compared to baseline.
No between-group difference was reported in the other blood or urine parameters investigated,
which included red blood cells, TG, sodium, potassium, chloride, albumin, and urine pH. Faecal bile
acids and SCFA were not altered (except for butyrate which was decreased).
A total of 30 and 28 adverse events were reported in the PGX and in the placebo group,
respectively. The most common adverse events were abdominal symptoms (n = 9 in PGX; n = 6 in the
placebo) and common cold.
Although the Panel considers that the magnitude of increases in AST and ALT levels observed in the
above-mentioned studies by Carabin et al. (2009) and by Reimer et al. (2013) are not clinically
relevant, the human data are not sufﬁcient to draw conclusions on the effect of chronic consumption
of PGX at the proposed maximum use levels on liver enzymes.
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3.9. Allergenicity
The applicant performed a scientiﬁc literature review to address the topic of allergy/allergic reaction
to the components of PGX following oral consumption. No references to published studies describing
an allergenic response to the oral consumption of konjac glucomannan, sodium alginate or xanthan
gum have been retrieved. Furthermore, the applicant indicated that approximately 800 million single
servings of PGX have been sold with no reports of allergenicity.
The Panel considers that the likelihood of allergic reactions to the NF is low.
4. Discussion
The NF is an off-white granular powder composed of three NSP: konjac glucomannan, xanthan
gum and sodium alginate. These NSP are mixed in a speciﬁc ratio, which has been claimed proprietary
and conﬁdential by the applicant, and processed by a proprietary process. The information provided on
the composition, the speciﬁcations, the batch-to-batch variability and the stability of the NF is sufﬁcient
and does not raise safety concerns. The production process is sufﬁciently described and does not raise
concerns about the safety of the NF.
The applicant intends to add the NF to a variety of foods such as yoghurt, breads, biscuits, cereals,
pasta and juices. The applicant also intends to market the NF in capsules (750 mg NF per capsule).
The recommended maximum daily intake of the NF from fortiﬁed foods and food supplements is 15 g.
The target population proposed by the applicant is adults from 18 to 64 years of age.
By using individual data from EU dietary surveys and the maximum proposed use levels for the NF,
the mean and 95th percentile anticipated daily intake of the NF were estimated (range of mean:
0.06–0.15 g/kg bw which corresponds to 4.2–10.5 g/day based on an adult bw of 70 kg; range of
95th percentile: 0.16–0.30 g/kg bw which corresponds to 11.2–21 g/day based on an adult bw of
70 kg). The Panel notes that the estimate of the 95th percentile anticipated daily intake of the NF
from fortiﬁed foods would exceed the recommended maximum daily intake as proposed by the
applicant (15 g/day). However, the Panel notes that this intake estimate is based on the conservative
assumption that all proposed food items from all food categories consumed by an individual actually
contain the NF at the maximum proposed level of use. The recommended maximum intake of the NF
from food supplements is 13.5 g/day (which corresponds to 0.19 g/kg bw per day for an adult bw of
70 kg).
Based on the nature of the NF, the Panel considers that the consumption of the NF is not
nutritionally disadvantageous.
Owing to its high water-holding capacity, when consumed with foods or beverages, the NF is able
to increase the volume and viscosity of gastric content, thereby affecting how material passes through
the digestive tract. A human study and an in vitro study on PGX indicate that the NF is fermented by
the human intestinal microbiota.
Considering the nature of the NF, the Panel considers that the information provided does not raise
concerns with respect to genotoxicity of the NF.
A subchronic toxicity study in Sprague–Dawley rats, which received a diet containing 0% (control),
1.25%, 2.5% or 5% of PGX for 13 weeks showed statistically signiﬁcant increases in serum activities
of ALT and AST in females in the high-dose group. These effects, which indicate a toxic effect on the
liver, were considered critical by the Panel. Therefore, the mid-dose, i.e. 2.5% PGX in the diet
corresponding to 1.8 g/kg bw per day, was set as the NOAEL for this study.
Based on the results of repeated dose toxicity studies with the individual NSP of PGX as well as
with other types of ﬁbre, the Panel considers that it is not possible to conclude whether or not
increases in ALT and AST activity in rats (as observed in the provided 90-day repeated-dose toxicity
study with PGX) are related to the three individual NSP of PGX or other ﬁbre in general or to exclude
that the increases in ALT and AST activity in rats are speciﬁc to the NF.
Two double-blind, placebo-controlled intervention studies in adults, who were randomised to
consume PGX (at doses up to 10 and 15 g/day) or placebo for 3 or 14 weeks, respectively, reported
minor within-group increases in AST and ALT levels in the PGX group at week-3 and week-6 as
compared to baseline, respectively. Although the Panel considers that the magnitude of increases in
AST and ALT levels observed in the above-mentioned studies by Carabin et al. (2009) and by Reimer
et al. (2013) are not clinically relevant, the human data are not sufﬁcient to draw conclusions on the
effect of chronic consumption of PGX at the proposed maximum use levels on liver enzymes.
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Considering the NOAEL of 1.8 g/kg bw per day and the highest mean and 95th percentile
anticipated daily intake of NF from fortiﬁed foods the margin of exposure (MoE) is 12 and 6,
respectively, whereas the MoE for the NF from food supplements is 9.
The Panel considers that the MoE for the NF at intended uses and use levels is not sufﬁcient for the
target population.
5. Conclusions
The Panel concludes that the safety of the novel food, PGX, for the intended uses and use levels as
proposed by the applicant, has not been established.
Documentation provided to EFSA
1) Letter from the European Commission to the European Food Safety Authority with the
request for a scientiﬁc opinion on the safety of ‘alginate-konjac-xanthan polysaccharide
complex (PGX)’ as a novel food ingredient. SANTE/E6/SS/ks Ref. Ares(2015)3221121, dated
31 July 2015.
2) Dossier on ‘alginate-konjac-xanthan polysaccharide complex (PGX)’ received by EFSA on
6 August 2015, which was submitted by InovoBiologic Inc.
3) Upon a request by EFSA for missing information, on 5 October 2015 EFSA received the
missing information as submitted by the applicant.
4) Initial assessment report carried out by the Food Safety Authority of Ireland: ‘Safety
Assessment of alginate-konjac-xanthan polysaccharide complex (PGX)’.
5) Member States’ comments and objections.
6) Response by the applicant to the initial assessment report and the Member States’ comments
and objections.
7) On 17 February 2016 and on 1 June 2016, EFSA sent requests to the applicant to provide
additional information.
8) On 5 April and on 28 July 2016, EFSA received additional information as submitted by the
applicant. Further clariﬁcations and additional information were also received on
1 December 2015 and on 20 May 2016.
9) During its meeting on 4 April 2017, the NDA Panel, having evaluated the data, adopted a
scientiﬁc opinion on the safety of alginate-konjac-xanthan polysaccharide complex (PGX) as a
novel food pursuant to Regulation (EC) No 258/97.
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